期刊文献+
共找到1,808篇文章
< 1 2 91 >
每页显示 20 50 100
The Effect of Predictive Nursing Intervention on Cardiac Function and Clinical Outcomes in CCU Patients with Acute Myocardial Infarction After Interventional Therapy
1
作者 Tingting Wang Cui Xia 《Journal of Clinical and Nursing Research》 2024年第8期237-242,共6页
Objective:To evaluate the impact of predictive nursing on the care of acute myocardial infarction(AMI)patients in the Coronary Care Unit(CCU)after interventional therapy.Methods:From September 2021 to September 2023,8... Objective:To evaluate the impact of predictive nursing on the care of acute myocardial infarction(AMI)patients in the Coronary Care Unit(CCU)after interventional therapy.Methods:From September 2021 to September 2023,84 AMI patients admitted to the CCU were randomly divided into two groups:the experimental group(42 patients)received predictive nursing,and the reference group(42 patients)received conventional nursing.Cardiac function and clinical outcomes were compared between the groups.Results:Before nursing,there was no difference in cardiac function between the two groups(P>0.05).After nursing,the cardiac function of the experimental group was better than that of the reference group(P<0.05).The clinical outcomes of the experimental group were better than those of the reference group(P<0.05).Before nursing,there was no difference in psychological scores between the two groups(P>0.05).After nursing,the psychological scores of the experimental group were lower than those of the reference group(P<0.05).Conclusion:Predictive nursing can improve the cardiac function and clinical outcomes of AMI patients after interventional therapy and can also regulate patients’negative psychological states. 展开更多
关键词 Predictive nursing CCU acute myocardial infarction Interventional therapy Cardiac function
下载PDF
Assessment of post-myocardial infarction lipid levels and management:Results from a tertiary care hospital of Pakistan
2
作者 Rubina Rauf Muhammad Ismail Soomro +3 位作者 Muhamman Nauman Khan Mukesh Kumar Najia Aslam Soomro Khawar Abbas Kazmi 《World Journal of Cardiology》 2024年第5期282-292,共11页
BACKGROUND Lipid treatment practices and levels in post-acute myocardial infarction(AMI)patients,which are crucial for secondary prevention.AIM To evaluate the lipid treatment practices and lipid levels in post-myocar... BACKGROUND Lipid treatment practices and levels in post-acute myocardial infarction(AMI)patients,which are crucial for secondary prevention.AIM To evaluate the lipid treatment practices and lipid levels in post-myocardial infarction(MI)patients at a tertiary care hospital in Pakistan.METHODS In this cross-sectional study,we analyzed patients who had experienced their first AMI event in the past 3 years.We assessed fasting and non-fasting lipid profiles,reviewed statin therapy prescriptions,and examined patient compliance.The recommended dose was defined as rosuvastatin≥20 mg or atorvastatin≥40 mg,with target total cholesterol levels set at<160 mg/dL and target low-density lipoprotein cholesterol(LDL-C)at<55 mg/dL.RESULTS Among 195 patients,71.3%were male,and the mean age was 57.1±10.2 years.The median duration since AMI was 36(interquartile range:10-48)months and 60% were diagnosed with ST-segment elevation MI.Only 13.8% of patients were advised to undergo lipid profile testing after AMI,88.7% of patients were on the recommended statin therapy,and 91.8% of patients were compliant with statin therapy.Only 11.5% had LDL-C within the target range and 71.7% had total cholesterol within the target range.Hospital admission in the past 12 months was reported by 14.4%,and the readmission rate was significantly higher among non-compliant patients(37.5%vs 5.6%).Subsequent AMI event rate was also significantly higher among non-compliant patients(43.8%vs 11.7%).CONCLUSION Our study highlights that while most post-AMI patients received the recommended minimum statin therapy dose,the inadequate practice of lipid assessment may compromise therapy optimization and raise the risk of subsequent events. 展开更多
关键词 Lipid profile DYSLIPIDEMIA acute myocardial infarction Secondary prevention Lipid lowering therapy
下载PDF
Long-Term Prognosis of Different Reperfusion Strategies for ST-Segment Elevation Myocardial Infarction in Chinese County-Level Hospitals:Insight from China Acute Myocardial Infarction Registry
3
作者 WU Chao ZHANG Qiong Yu +11 位作者 LI Ling ZHANG Xu Xia CAI Yong Chen YANG Jin Gang XU Hai Yan ZHAO Yan Yan WANG Yang LI Wei JIN Chen GAO Xiao Jin YANG Yue Jin QIAO Shu Bin 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2023年第9期826-836,共11页
Objective To evaluate the long-term prognosis of patients with ST-segment elevation myocardial infarction(STEMI)treated with different reperfusion strategies in Chinese county-level hospitals Methods A total of 2,514 ... Objective To evaluate the long-term prognosis of patients with ST-segment elevation myocardial infarction(STEMI)treated with different reperfusion strategies in Chinese county-level hospitals Methods A total of 2,514 patients with STEMI from 32 hospitals participated in the China Acute Myocardial Infarction registry between January 2013 and September 2014.The success of fibrinolysis was assessed according to indirect measures of vascular recanalization.The primary outcome was 2-year mortality.Results Reperfusion therapy was used in 1,080 patients(42.9%):fibrinolysis(n=664,61.5%)and primary percutaneous coronary intervention(PCI)(n=416,38.5%).The most common reason for missing reperfusion therapy was a prehospital delay>12 h(43%).Fibrinolysis[14.5%,hazard ratio(HR):0.59,95%confidence interval(CI)0.44–0.80]and primary PCI(6.8%,HR=0.32,95%CI:0.22–0.48)were associated with lower 2-year mortality than those with no reperfusion(28.5%).Among fibrinolysistreated patients,510(76.8%)achieved successful clinical reperfusion;only 17.0%of those with failed fibrinolysis underwent rescue PCI.There was no difference in 2-year mortality between successful fibrinolysis and primary PCI(8.8%vs.6.8%,HR=1.53,95%CI:0.85–2.73).Failed fibrinolysis predicted a similar mortality(33.1%)to no reperfusion(33.1%vs.28.5%,HR=1.30,95%CI:0.93–1.81).Conclusion In Chinese county-level hospitals,only approximately 2/5 of patients with STEMI underwent reperfusion therapy,largely due to prehospital delay.Approximately 30%of patients with failed fibrinolysis and no reperfusion therapy did not survive at 2 years.Quality improvement initiatives are warranted,especially in public health education and fast referral for mechanical revascularization in cases of failed fibrinolysis. 展开更多
关键词 acute myocardial infarction Reperfusion therapy Rural OUTCOME
下载PDF
Effect of fibrinolytic therapy on ST-elevation myocardial infarction clinical outcomes during the COVID-19 pandemic:A systematic review and meta-analysis
4
作者 Anwar Khedr Hussam Al Hennawi +14 位作者 Muhammed Khuzzaim Khan Mostafa Elbanna Abbas B Jama Ekaterina Proskuriakova Hisham Mushtaq Mikael Mir Sydney Boike Ibtisam Rauf Aalaa Eissa Meritxell Urtecho Thoyaja Koritala Nitesh Jain Lokesh Goyal Salim Surani Syed A Khan 《World Journal of Cardiology》 2023年第6期309-323,共15页
BACKGROUND ST-elevation myocardial infarction(STEMI)is the result of transmural ischemia of the myocardium and is associated with a high mortality rate.Primary percutaneous coronary intervention(PPCI)is the recommende... BACKGROUND ST-elevation myocardial infarction(STEMI)is the result of transmural ischemia of the myocardium and is associated with a high mortality rate.Primary percutaneous coronary intervention(PPCI)is the recommended first-line treatment strategy for patients with STEMI.The timely delivery of PPCI became extremely challenging for STEMI patients during the coronavirus disease 2019(COVID-19)pandemic,leading to a projected steep rise in mortality.These delays were overcome by the shift from first-line therapy and the development of modern fibrinolytic-based reperfusion.It is unclear whether fibrinolytic-based reperfusion therapy is effective in improving STEMI endpoints.AIM To determine the incidence of fibrinolytic therapy during the COVID-19 pandemic and its effects on STEMI clinical outcomes.METHODS PubMed,Google Scholar,Scopus,Web of Science,and Cochrane Central Register of Controlled Trials were queried from January 2020 up to February 2022 to identify studies investigating the effect of fibrinolytic therapy on the prognostic outcome of STEMI patients during the pandemic.Primary outcomes were the incidence of fibrinolysis and the risk of all-cause mortality.Data were meta-analyzed using the random effects model to derive odds ratios(OR)and 95%confidence intervals.Quality assessment was carried out using the Newcastle-Ottawa scale.RESULTS Fourteen studies including 50136 STEMI patients(n=15142 in the pandemic arm;n=34994 in the pre-pandemic arm)were included.The mean age was 61 years;79%were male,27%had type 2 diabetes,and 47%were smokers.Compared with the pre-pandemic period,there was a significantly increased overall incidence of fibrinolysis during the pandemic period[OR:1.80(1.18 to 2.75);I2=78%;P=0.00;GRADE:Very low].The incidence of fibrinolysis was not associated with the risk of all-cause mortality in any setting.The countries with a low-and middle-income status reported a higher incidence of fibrinolysis[OR:5.16(2.18 to 12.22);I2=81%;P=0.00;GRADE:Very low]and an increased risk of all-cause mortality in STEMI patients[OR:1.16(1.03 to 1.30);I2=0%;P=0.01;GRADE:Very low].Meta-regression analysis showed a positive correlation of hyperlipidemia(P=0.001)and hypertension(P<0.001)with all-cause mortality.CONCLUSION There is an increased incidence of fibrinolysis during the pandemic period,but it has no effect on the risk of all-cause mortality.The low-and middle-income status has a significant impact on the all-cause mortality rate and the incidence of fibrinolysis. 展开更多
关键词 ST-elevation myocardial infarction myocardial infarction thrombolytic therapy FIBRINOLYSIS COVID-19 Pandemics
下载PDF
Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction 被引量:4
5
作者 Miruna Mihaela Micheu Maria Dorobantu 《World Journal of Stem Cells》 SCIE CAS 2017年第4期68-76,共9页
In spite of modern treatment, acute myocardial infarction(AMI) still carries significant morbidity and mortality worldwide. Even though standard of care therapy improves symptoms and also long-term prognosis of patien... In spite of modern treatment, acute myocardial infarction(AMI) still carries significant morbidity and mortality worldwide. Even though standard of care therapy improves symptoms and also long-term prognosis of patients with AMI, it does not solve the critical issue, specifically the permanent damage of cardiomyocytes. As a result, a complex process occurs, namely cardiac remodeling, which leads to alterations in cardiac size, shape and function. This is what has driven the quest for unconventional therapeutic strategies aiming to regenerate the injured cardiac and vascular tissue. One of the latest breakthroughs in this regard is stem cell(SC) therapy. Based on favorable data obtained in experimental studies, therapeutic effectiveness of this innovative therapy has been investigated in clinical settings. Of various cell types used in the clinic, autologous bone marrow derived SCs were the first used to treat an AMI patient, 15 years ago. Since then, we have witnessed an increasing body of data as regards this cutting-edge therapy. Although feasibility and safety of SC transplant have been clearly proved, it's efficacy is still under dispute. Conducted studies and meta-analysis reported conflicting results, but there is hope for conclusive answer to be provided by the largest ongoing trial designed to demonstrate whether this treatment saves lives. In the meantime, strategies to enhance the SCs regenerative potential have been applied and/or suggested, position papers and recommendations have been published. But what have we learned so far and how can we properly use the knowledge gained? This review will analytically discuss each of the above topics, summarizing the current state of knowledge in the field. 展开更多
关键词 Bone marrow stem cells acute myocardial infarction Cell therapy Cardiac regeneration REMODELING
下载PDF
Direct Coronary Intervention Therapy in Patients with Acute Myocardial Infarction
6
作者 朱铁兵 杨志健 +4 位作者 王连生 马根山 曹克将 黄峻 马文珠 《Journal of Nanjing Medical University》 2002年第3期127-129,共3页
Objective To introduce the initial experience of direct percutaneous transluminal coronary angioplasty(PTCA) and intracoronary stenting in patients with acute myocardial infarction(AMI) from October 1998 to November ... Objective To introduce the initial experience of direct percutaneous transluminal coronary angioplasty(PTCA) and intracoronary stenting in patients with acute myocardial infarction(AMI) from October 1998 to November 2001 in our hospital. Methods Primary PTCA was performed in 38 patients with acute myocardial infarction.29 cases were 20 male and 9 female, ranging in age from 30 to 76 old years.23 cases had anterior and 15 had inferior wall infarction. The patients we chose for direct coronary intervention therapy had stable hemodynamics. Of the 38 infarct related arteries (IRA), 23 were left anterior descend arteries (LAD), 4 left circumflex (LCX) and 11 right coronary arteries (RCA). 33 IRA were TIMI 0 flow and 5 TIMI 1 flow. The indications for coronary stent implantation were: ① Acute reocclusion and high risk of reocclusion due to initial dissection after PTCA; ② Severe residual stenosis (stenosis of diameter≥50%) after repeated balloon dilation; ③ No response to recurrent infusions of Nitroglycerin in Obviously elastic recoil. Results Of the 38 patients with AMI, PTCA was successful in 35 Two patients were given up because 014 guide wire entered into false lumen. One was selected for emergency coronary artery bypass graft because of LAD infarct related artery accompanied by 70%stenosis of left main. 35 intracoronary stents were implanted.16 patients were followed up, of whom 2 patients had restenosis and were successful in the second attempt. Conclusion Direct PTCA and stent implantation are effective and safe means of treatment for AMI and stent implantation can prevent and cure the acute reocclusion after PTCA. 展开更多
关键词 acute myocardial infarction percutaneous transluminal coronary angioplasty stents therapy
下载PDF
EFFECT OF REPERFUSION THERAPY ON SOLUBLE CELL ADHESION MOLECULES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
7
作者 谢玉才 沈卫峰 +3 位作者 陆国平 龚兰生 周同 印彤 《Medical Bulletin of Shanghai Jiaotong University》 CAS 2000年第1期34-36,共3页
Objective To observe the changes of serum soluble intercellular adhesion moiecuie type-1(ICAM-1) and E-selectin in patients with acute myocardial inlarction (AMI) receiving reperfusiontherapy. Methods Peripheral venou... Objective To observe the changes of serum soluble intercellular adhesion moiecuie type-1(ICAM-1) and E-selectin in patients with acute myocardial inlarction (AMI) receiving reperfusiontherapy. Methods Peripheral venous blood samples were taken from 21 patients with AMI before and4,8,12,24,48,72h after thrombolytic treatment or direct percutaneous transluminal coronary angioplasty (PTCA).Blood samples from 16 control subjects were drawn for one time. Serum concentration of ICAM-1 and E-selectinwas determined by double antibodies sandwich enzyme-linked immunosorbent assay. Results Serum levels ofICAM-1 and E-selectin were higher in patients with AMI than those in controls. Sixteen patients with AMIand successful roperfusion therapy had signifcantly reduction in serum concentration of ICAM-1 and E-selectinat 24 and 48h, but had a peak at 4h. The remaining live patients who failed in mperfusion theropy didn’t show anysignificant changes in these values. Conclusion The serum concentration of ICAM-1 and E-selectin waselevated significantly in patients with AMI Successful reperfusion therapy can reduce the increased serumconcentration. 展开更多
关键词 soluble intercellular adhesion molecule type-1 E-selectin reperfusion therapy acute myocardial infarction
下载PDF
Efficacy and safety of aspirin antiplatelet therapy within 48 h of symptom onset in patients with acute stroke 被引量:1
8
作者 Jian-Quan Zhang Zhi-Bin Pan 《World Journal of Clinical Cases》 SCIE 2023年第32期7814-7821,共8页
BACKGROUND Aspirin is a widely used antiplatelet agent that reduces the risk of recurrent ischemic stroke and other vascular events.However,the optimal timing and dose of aspirin initiation after an acute stroke remai... BACKGROUND Aspirin is a widely used antiplatelet agent that reduces the risk of recurrent ischemic stroke and other vascular events.However,the optimal timing and dose of aspirin initiation after an acute stroke remain controversial.AIM To evaluate the efficacy and safety of aspirin antiplatelet therapy within 48 h of symptom onset in patients with acute stroke.METHODS We conducted a randomized,open-label,controlled trial in 60 patients with acute ischemic or hemorrhagic stroke who were admitted to our hospital within 24 h of symptom onset.Patients were randomly assigned to receive either aspirin 300 mg daily or no aspirin within 48 h of stroke onset.The primary outcome was the occurrence of recurrent stroke,myocardial infarction,or vascular death within 90 d.The secondary outcomes were functional outcomes at 90 d measured using the modified Rankin Scale(mRS),incidence of bleeding complications,and mortality rate.RESULTS The mean age of the patients was 67.8 years and 55%of them were male.The median time from stroke onset to randomization was 12 h.The baseline characteristics were well balanced between the two groups.The primary outcome occurred in 6.7%of patients in the aspirin group and 16.7%of patients in the no aspirin group(relative risk=0.40,95%confidence interval:0.12-1.31,P=0.13).The mRS score at 90 d was significantly lower in the aspirin group than in the no aspirin group(median,2 vs 3,respectively;P=0.04).The incidence of bleeding complications was similar between the groups(6.7%vs 6.7%,P=1.00).The mortality rates were also comparable between the two groups(10%vs 13.3%,P=0.69).CONCLUSION Aspirin use is associated with favorable functional outcomes but does not significantly reduce the risk of recurrent vascular events.Its acceptable safety profile is comparable to that of no aspirin.Further studies with larger sample sizes and longer follow-up periods are needed to confirm these findings. 展开更多
关键词 ASPIRIN acute stroke Antiplatelet therapy Recurrent stroke Recurrent vascular events myocardial infarction
下载PDF
Stenting versus non-stenting treatment of intermediate stenosis culprit lesion in acute ST-segment elevation myocardial infarction: a multicenter random- ized clinical trial 被引量:14
9
作者 Jing DAI Shu-Zheng LYU +12 位作者 Yun-Dai CHEN Xian-Tao SONG Min ZHANG Wei-Min LI Yang ZHENG Shang-Yu WEN Shao-Ping NIE Yu-Jie ZENG Hai GAO Yi-Tong MA Shu-Yang ZHANG Li-Jun GUO Zheng ZHANG 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2017年第2期108-117,共10页
Background The benefit/risk ratio of stenting in acute ST-segment elevation myocardial infarction (STEMI) patients with single vessel intermediate stenosis culprit lesions merits further study, therefore the subject... Background The benefit/risk ratio of stenting in acute ST-segment elevation myocardial infarction (STEMI) patients with single vessel intermediate stenosis culprit lesions merits further study, therefore the subject of the present study. Methods and results It was a pro- spective, multicenter, randomized controlled trial. Between April 2012 and July 2015, 399 acute STEMI patients with single vessel disease and intermediate (40%-70%) stenosis of the culprit lesion before or after aspiration thrombectomy and/or intracoronary tirofiban (15 pg/kg) were enrolled and were randomly assigned (h 1) to stenting group (n = 201) and non-stenting group (n = 198). In stenting group, patients received pharmacologic therapy plus standard percutaneous coronary intervention (PCI) with stent implantation. In non-stenting group, pa- tients received pharmacologic therapy and PCI (thrombectomy), but without dilatation or stenting. Primary endpoint was 12-month rate of major adverse cardiac and eerebrovascular events (MACCE), a composite of cardiac death, non-fatal myocardial infarction (M1), repeat re- vascularization and stroke. Secondary endpoints were 12-month rates of all cause death, ischemia driven admission and bleeding complica- tion. Median follow-up time was 12.4 ~ 3.1 months. At 12 months, MACCE occurred in 8.0% of the patients in stenting group, as compared with 15.2% in the non-stenting group (adjusted HR: 0.42, 95% Ch 0.19-0.89, P = 0.02). The stenting group had lower non-fatal MI rate than non-stenting group, (1.5% vs. 5.5%, P = 0.03). The two groups shared similar cardiac death, repeat revascularization, stroke, all cause death, ischemia driven readmission and bleeding rates at 12 months. Conclusions Stent implantation had better efficacy and safety in reducing MACCE risks among acute STEMI patients with single vessel intermediate stenosis culprit lesions. 展开更多
关键词 acute myocardial infarction Anti-thrombotic therapy Clinical trial Primary percutaneous coronary intervention Stent ST-segment elevation myocardial infarction
下载PDF
Predictors and in-hospital prognosis of recurrent acute myocardial infarction 被引量:11
10
作者 Cheng-Fu CAO Su-Fang LI +1 位作者 Hong CHEN Jun-Xian SONG 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2016年第10期836-839,共4页
Objective To investigate the contributing factors and in-hospital prognosis of patients with or without recurrent acute myocardial infarction (AMI). Methods A total of 1686 consecutive AMI patients admitted to Pekin... Objective To investigate the contributing factors and in-hospital prognosis of patients with or without recurrent acute myocardial infarction (AMI). Methods A total of 1686 consecutive AMI patients admitted to Peking University People's Hospital from January 2010 to December 2015 were recruited. Their clinical characteristics were retrospectively compared between patients with or without a recurrent AMI. Then multivariable logistic regression was used to estimate the predictors of recurrent myocardial infarction. Results Recurrent AMI patients were older (69.3 ± 11.5 vs. 64.7 ± 12.8 years, P 〈 0.001) and had a higher prevalence of diabetes mellitus (DM) (52.2% vs. 35.0%, P 〈 0.001) compared with incident AMI patients, they also had worse heart function at admission, more severe coronary disease and lower reperfusion therapy. Age (OR = 1.03, 95% CI: 1.02-1.05; P 〈 0.001), DM (OR = 1.86, 95% CI: 1.37-2.52; P 〈 0.001) and reperfusion therapy (OR = 0.74; 95% CI: 0.52-0.89; P 〈 0.001) were independent risk factors for recurrent AMI Recurrent AMI patients had a higher in-hospital death rate (12.1% vs. 7.8%, P = 0.039) than incident AMI patients. Conclusions Recurrent AMI patients presented with more severe coronary artery conditions. Age, DM and reperfusion therapy were independent risk factors for recurrent AMI, and recurrent AM1 was related with a high risk of in-hospital death. 展开更多
关键词 acute myocardial infarction Age Diabetes mellitus In-hospital prognosis Reperfusion therapy
下载PDF
Effectiveness and safety of antithrombotic strategies in elderly patients with acute myocardial infarction 被引量:1
11
作者 Elisa Rondano Marzia Bertolazzi +8 位作者 Alessandro Galluzzo Ludovica Maltese Paolo Caccianotti Sergio Macciò Stefano Mazza Maria Virginia Di Ruocco Serena Favretto Eraldo Occhetta Francesco Rametta 《World Journal of Cardiology》 2020年第11期513-525,共13页
BACKGROUND Elderly patients represent a rapidly growing part of the population more susceptible to acute coronary syndromes and their complications.However,literature evidence is lacking in this clinical setting.AIM T... BACKGROUND Elderly patients represent a rapidly growing part of the population more susceptible to acute coronary syndromes and their complications.However,literature evidence is lacking in this clinical setting.AIM To describe the clinical features,in-hospital management and outcomes of“elderly”patients with myocardial infarction treated with antiplatelet and/or anticoagulation therapy.METHODS This study was a retrospective analysis of all consecutive patients older than 80 years admitted to the Division of Cardiology of St.Andrea Hospital of Vercelli from January 2018 to December 2018 due to ST-elevation myocardial infarction(STEMI)or non-ST elevation myocardial infarction(NSTEMI).Clinical and laboratory data were collected for each patient,as well as the prevalence of previous or in-hospital atrial fibrillation(AF).In-hospital management,consisting of an invasive or conservative strategy,and the anti-thrombotic therapy used are described.Outcomes evaluated at 1 year follow-up included an efficacy ischemic endpoint and a safety bleeding endpoint.RESULTS Of the 105 patients enrolled(mean age 83.9±3.6 years,52.3%males),68(64.8%)were admitted due to NSTEMI and 37(35.2%)due to STEMI.Among the STEMI patients,34(91.9%)underwent coronary angiography and all of them were treated with percutaneous coronary intervention(PCI);among the NSTEMI patients,42(61.8%)were assigned to an invasive strategy and 16(38.1%)of them underwent a PCI.No significant difference between the groups was found concerning the prevalence of previous or in-hospital de-novo AF.10.5%of the whole population received triple antithrombotic therapy and 9.5%single antiplatelet therapy plus oral anticoagulation(OAC),with no significant difference between the subgroups,although a higher number of STEMI patients received dual antiplatelet therapy without OAC as compared with NSTEMI patients.A low rate of in-hospital death(5.7%)and 1-year cardiovascular death(3.3%)was registered.Seven(7.8%)patients experienced major adverse cardiovascular events,while the rate of minor and major bleeding at 1-year follow-up was 10%and 2.2%,respectively,with no difference between NSTEMI and STEMI patients.CONCLUSION In this real-world study,a tailored evaluation of an invasive strategy and antithrombotic therapy resulted in a low rate of adverse events in elderly patients hospitalized with acute myocardial infarction. 展开更多
关键词 Antiplatelet therapy Anticoagulant therapy Elderly patients SAFETY acute myocardial infarction
下载PDF
A comparative study of primary coronary stenting andintravenous thrombolysis for acute myocardial infarctionusing^(99m) Tc-MIBI SPECT imaging
12
作者 WANG Tie, HU Da-Yi, LI Tian-Chang, JIA San-Qing (Beijing Chaoyang Hospital, Affiliale of Capital University of Medial Sciences, Beijing 100020 ) 《Nuclear Science and Techniques》 SCIE CAS CSCD 2000年第4期210-212,共3页
The theraputic effectiveness of primary coronary stenting was evaluated and compared with that of intravenous thrombolysis for acute myocardial infarction (AMI) using99m Tc-MIBI myocardial SPECT imaging. 42 patients w... The theraputic effectiveness of primary coronary stenting was evaluated and compared with that of intravenous thrombolysis for acute myocardial infarction (AMI) using99m Tc-MIBI myocardial SPECT imaging. 42 patients with AMI were undergone primary coronary stenting (stenting group, 23 patients) or intravenous thrombolysis therapy (thrombolysis group, 19 patients). 99mTc-MIBI myocardium SPECT imaging was performed before and 1 week after steming or thrombolysis therapy. The left ventricular myocardium of each patient was divided into 20 segments. The semiquantitative score of myocardial 99mTc-MIBI uptake was eXPressed with a five-point scoring system: 0 = normal; 1 = equivocal; 2 = mild defect; 3 = severe defect; 4 = absence of activity. The scores of scanning before stenting or intravenous throm-bolysis was SBS. The scores of scaning after stenting or intravenous thrombolysis was SAS. Deducting SAS from SBS was SDS. A comparison was made between the steming group and thrombolysis group: SBS was 41.3+9.8 and 39.4+7.9 (t=1.2, p <0.05); SAS was 17.8+6.4 and 27.3+6.7 (t=5.8, p <0.01); SDS was 24.5+4.2 and 12.2+2.3 (t = 7.3, P <0.01). In the 193 defect segments before stenting, 106 segments (54.9%) restored to normal after steming. In the 149 defect segments before intravenous thrombolysis, 61 segments (40.9%) restored to normal after thrombolysis therapy. Comparing between steming group and thrombolysis group in the improved rate of myocardial perfusion defect scores there was a significant difference (p <0.01). 99mTc-MIBI myocardial SPECT imaging has been proved to be an objective parameter for evaluating the therapeutic effectiveness of the stenting and the intravenous thrombolysis in the treatment of AMI. The results indicated that primary coronary stenting seems to be more effective than intravenous thrombolysis. 展开更多
关键词 ^99MTC-MIBI 锝99 放射性核素标记 溶栓疗法 心肌疾病 放射性药物 心肌显像 放射性核素显像 诊断
全文增补中
Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction:A randomized non-inferiority trial 被引量:1
13
作者 Xingshan Zhao Yidan Zhu +21 位作者 Zheng Zhang Guizhou Tao Haiyan Xu Guanchang Cheng Wen Gao Liping Ma Liping Qi Xiaoyan Yan Haibo Wang Qingde Xia Yuwang Yang Wanke Li Juwen Rong Limei Wang Yutian Ding Qiang Guo Wanjun Dang Chen Yao Qin Yang Runlin Gao Yangfeng Wu Shubin Qiao 《Chinese Medical Journal》 SCIE CAS CSCD 2024年第3期312-319,共8页
Background:A phase II trial on recombinant human tenecteplase tissue-type plasminogen activator(rhTNK-tPA)has previously shown its preliminary efficacy in ST elevation myocardial infarction(STEMI)patients.This study w... Background:A phase II trial on recombinant human tenecteplase tissue-type plasminogen activator(rhTNK-tPA)has previously shown its preliminary efficacy in ST elevation myocardial infarction(STEMI)patients.This study was designed as a pivotal postmarketing trial to compare its efficacy and safety with rrecombinant human tissue-type plasminogen activator alteplase(rt-PA)in Chinese patients with STEMI.Methods:In this multicenter,randomized,open-label,non-inferiority trial,patients with acute STEMI were randomly assigned(1:1)to receive an intravenous bolus of 16 mg rhTNK-tPA or an intravenous bolus of 8 mg rt-PA followed by an infusion of 42 mg in 90 min.The primary endpoint was recanalization defined by thrombolysis in myocardial infarction(TIMI)flow grade 2 or 3.The secondary endpoint was clinically justified recanalization.Other endpoints included 30-day major adverse cardiovascular and cerebrovascular events(MACCEs)and safety endpoints.Results:From July 2016 to September 2019,767 eligible patients were randomly assigned to receive rhTNK-tPA(n=384)or rt-PA(n=383).Among them,369 patients had coronary angiography data on TIMI flow,and 711 patients had data on clinically justified recanalization.Both used a–15%difference as the non-inferiority efficacy margin.In comparison to rt-PA,both the proportion of patients with TIMI grade 2 or 3 flow(78.3%[148/189]vs.81.7%[147/180];differences:–3.4%;95%confidence interval[CI]:–11.5%,4.8%)and clinically justified recanalization(85.4%[305/357]vs.85.9%[304/354];difference:–0.5%;95%CI:–5.6%,4.7%)in the rhTNK-tPA group were non-inferior.The occurrence of 30-day MACCEs(10.2%[39/384]vs.11.0%[42/383];hazard ratio:0.96;95%CI:0.61,1.50)did not differ significantly between groups.No safety outcomes significantly differed between groups.Conclusion:rhTNK-tPA was non-inferior to rt-PA in the effect of improving recanalization of the infarct-related artery,a validated surrogate of clinical outcomes,among Chinese patients with acute STEMI.Trial registration:www.ClinicalTrials.gov(No.NCT02835534). 展开更多
关键词 thrombolytic therapy rhTNK-tPA Randomized controlled trial ST elevation myocardial infarction
原文传递
Atrioventricular block complicating inferior acute myocardial infarction treated with thrombolytic therapy 被引量:2
14
作者 陈士良 冯胜强 张清华 《Chinese Medical Journal》 SCIE CAS CSCD 2001年第10期31-34,104,共5页
Objective To investigate the influence and mechanism of incidence of atrioventricular block (AVB) treated with thrombolytic therapy in acute inferior myocardial infarction (AIMI).Methods A total of 46 patients with A... Objective To investigate the influence and mechanism of incidence of atrioventricular block (AVB) treated with thrombolytic therapy in acute inferior myocardial infarction (AIMI).Methods A total of 46 patients with AIMI were divided into the thrombolytic group (n = 23) and the nonthrornboytic group (n = 23). Intravenous or intracoronary urokinase was given to the former group. We observed the advancing courses of AVB, and further assessed the relationship between occurrence of AVB and stenosis of infarct-related artery (IRA) with coronary angiography.Results Two cases died of Ⅲ o AVB in the non-thrombolytic group, but none was found in the thrombolytic group. The occurrence rate of AVB was similar in both groups; but that of Ⅲ ° AVB was much lower in the thrombolytic group (4 cases) than that in the non-thrombolytic group (11 cases, P < 0.05), and the duration of AVB decreased from 201 ± 113 hours to 102±60 hours after thrombolytic therapy ( P<0.01 ),which was mainly due to the decrease of AVB in the vanishing interval, but not in the developing interval.The coronary angiography demonstrated that there were an increasing reperfusion flow and a decreasing coronary stenosis of the infarct-related artery after thrombolytic therapy.Conclusion Thrombolytic therapy can reduce the incidence of severe AVB, shorten its duration and decrease the mortality by increasing the coronary reperfusion flow in the patients with AIMI. 展开更多
关键词 inferior wall · myocardial infarction · atrioventricular block · thrombolytic therapy · reperfusion · coronary artery angiography
原文传递
血清Cx43、Gal-9水平对老年急性脑梗死患者超早期静脉溶栓治疗预后的评估价值
15
作者 蒋召芹 穆永芳 +1 位作者 刘宇鹏 聂亚冬 《国际检验医学杂志》 CAS 2024年第14期1715-1719,共5页
目的探讨血清间隙连接蛋白43(Cx43)、半乳糖凝集素-9(Gal-9)水平对老年急性脑梗死(ACI)患者超早期静脉溶栓治疗预后的评估价值。方法选取2020年9月至2022年9月在该院行超早期静脉溶栓治疗的106例老年ACI患者作为研究组,另外选取同期来... 目的探讨血清间隙连接蛋白43(Cx43)、半乳糖凝集素-9(Gal-9)水平对老年急性脑梗死(ACI)患者超早期静脉溶栓治疗预后的评估价值。方法选取2020年9月至2022年9月在该院行超早期静脉溶栓治疗的106例老年ACI患者作为研究组,另外选取同期来该院体检的100例体检健康者作为健康组。采用酶联免疫吸附试验(ELISA)检测所有研究对象的血清Cx43、Gal-9水平。治疗2周后参考美国国立卫生院卒中量表(NIHSS)评分将106例老年ACI患者分为预后良好组(81例)与预后不良组(25例)。采用受试者工作特征(ROC)曲线分析血清Cx43、Gal-9水平对老年ACI患者超早期静脉溶栓治疗预后的评估价值,采用多因素Logistic回归分析探讨老年ACI患者超早期静脉溶栓治疗预后不良的影响因素。结果研究组血清Cx43、Gal-9水平高于健康组(P<0.05);预后不良组血清Cx43、Gal-9水平高于预后良好组(P<0.05);血清Cx43、Gal-9预测老年ACI患者预后不良的曲线下面积(AUC)分别为0.721(95%CI:0.673~0.758)、0.837(95%CI:0.787~0.886),二者联合预测的AUC为0.901(95%CI:0.857~0.946)。预后不良组高血压占比高于预后良好组(P<0.05);多因素Logistic回归分析显示,高血压(OR=3.487,95%CI:1.564~7.773),血清Cx43≥106.53 pg/mL(OR=4.586,95%CI:1.982~10.611),血清Gal-9≥11.84 ng/mL(OR=4.345,95%CI:1.957~9.648)是老年ACI患者超早期静脉溶栓治疗预后不良的危险因素(P<0.05)。结论血清Cx43、Gal-9在老年ACI患者中均呈高表达,可用于评估老年ACI患者超早期静脉溶栓治疗的预后,二者联合检测的评估价值更高。 展开更多
关键词 间隙连接蛋白43 半乳糖凝集素-9 老年 急性脑梗死 静脉溶栓治疗 预后
下载PDF
血府逐瘀汤对STEMI病人PCI术后炎症指标、再灌注后心功能及生存质量的影响
16
作者 张望 陈敏娜 +6 位作者 邢雪 赵运 吕玮坤 董欢乐 王文丽 康启 董静 《中西医结合心脑血管病杂志》 2024年第13期2382-2388,共7页
目的:探讨血府逐瘀汤对ST段抬高型心肌梗死(STEMI)病人经皮冠状动脉介入治疗(PCI)术后炎症指标及再灌注后心功能及生存质量的影响。方法:选取2020年1月1日—2021年12月31日于我院接受PCI治疗的STEMI病人244例作为研究对象,采用计算机随... 目的:探讨血府逐瘀汤对ST段抬高型心肌梗死(STEMI)病人经皮冠状动脉介入治疗(PCI)术后炎症指标及再灌注后心功能及生存质量的影响。方法:选取2020年1月1日—2021年12月31日于我院接受PCI治疗的STEMI病人244例作为研究对象,采用计算机随机化法分为研究组和对照组,每组122例。研究组给予血府逐瘀汤+PCI术后常规基础治疗,对照组给予PCI术后常规基础治疗,两组病人均随访6个月。对比两组主要心脑血管不良事件(MACCE)发生情况、心肌梗死多维度量表(MIDAS)评分、美国纽约心脏协会(NYHA)心功能分级、不良反应发生情况、中医临床症状积分、中医证候疗效、左心室重构情况及炎性因子[白细胞介素-6(IL-6)、内皮素-1(ET-1)、一氧化氮(NO)以及基质金属蛋白酶-9(MMP-9)]水平。结果:研究组MACCE总发生率低于对照组,NYHA心功能分级改善情况优于对照组,中医证候疗效优于对照组(P<0.05)。治疗后,两组MIDAS评分均较治疗前降低,且研究组低于对照组(P<0.05)。治疗后,两组中医临床症状积分均较治疗前下降,且研究组低于对照组(P<0.05)。治疗后,两组左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)降低,左室射血分数(LVEF)升高,且研究组LVESD、LVEDD低于对照组,LVEF高于对照组(P<0.05)。治疗后,两组IL-6、ET-1、MMP-9降低,NO升高,且研究组IL-6、ET-1、MMP-9低于对照组,NO高于对照组(P<0.05)。结论:血府逐瘀汤应用于STEMI病人PCI术后能显著提高病人的整体生存质量,降低MACCE发生风险,改善心功能,减轻炎症反应,有利于病人预后。 展开更多
关键词 急性心肌梗死 经皮冠状动脉介入治疗 血府逐瘀汤 心功能 生存质量
下载PDF
急性心肌梗死冠脉介入治疗前TyG及心率变异性的监测价值及预后影响因素分析
17
作者 李志 邬春梦 雷锐 《临床和实验医学杂志》 2024年第17期1814-1818,共5页
目的 探讨急性心肌梗死(AMI)冠脉介入治疗前后甘油三酯葡萄糖指数(TyG)及心率变异性的监测价值及预后影响因素。方法 选取2020年3月到2023年3月佳木斯市中心医院收治的90例AMI患者进行回顾性分析,所有患者均采取冠脉介入治疗,对所有患... 目的 探讨急性心肌梗死(AMI)冠脉介入治疗前后甘油三酯葡萄糖指数(TyG)及心率变异性的监测价值及预后影响因素。方法 选取2020年3月到2023年3月佳木斯市中心医院收治的90例AMI患者进行回顾性分析,所有患者均采取冠脉介入治疗,对所有患者进行1年门诊复查随访,分析其治疗情况及预后,并对比其治疗前后TyG及心率变异性变化,建立受试者操作特征(ROC)曲线,分析治疗后TyG及心率变异性指标对AMI后不良心血管事件的诊断价值。随后将术后1年发生心血管不良事件的20例患者分为预后不良组,其余为预后良好组。多因素Logistics回归分析影响AMI介入治疗预后的因素。结果 90例AMI患者27例行急诊PCI,63例行择期PCI,单支血管病变患者42例,2支及以上48例,通过对患者进行1年随访,20例患者发生不良心血管事件。治疗后TyG为7.28±1.49,低于治疗前,治疗后全程相邻R-R间期差值均方根值(rMSSD)、全部正常窦性心搏R-R间期标准差(SDNN)及5 min心搏间期均值标准差(SDANN)分别为(37.62±6.24) ms、(120.51±12.37) ms、(126.62±16.66) ms,均高于治疗前,差异均有统计学意义(P<0.05)。TyG联合心率变异性指标的诊断敏感度为71.57%,特异度为83.56%,联合诊断明显高于单一指标诊断;预后良好组与预后不良组患者性别、体重指数、饮酒史、PCI治疗时机、左心室射血分数、预后危险(TIMI)评分比较,差异均无统计学意义(P>0.05),预后良好组与预后不良组患者年龄、发病到PCI时间、合并基础疾病、Killip心功能分级、吸烟史、冠脉病变支数、TIMI评分、TyG、rMSSD、SDNN、SDANN比较,差异均有统计学意义(P<0.05)。结果显示,年龄、发病到PCI时间、Killip心功能分级、TyG、rMSSD、SDNN、SDANN是影响AMI介入治疗预后的独立危险因素(P<0.05)。结论 AMI采取冠脉介入治疗术后1年不良心血管事件发生率达22.22%,通过冠脉介入治疗可降低患者机体TyG水平,改善心率变异性;治疗后采用TyG联合心率变异性指标和提升对不良心血管事件的诊断价值;进一步分析发现,年龄、发病到PCI时间、Killip心功能分级、TyG及心率变异性为其预后不良的影响因素。 展开更多
关键词 甘油三酯葡萄糖指数 心率变异性 急性心肌梗死 冠状动脉介入治疗
下载PDF
DWI-ASPECTS评分联合血清Hcy、LDL-C、Lp-PLA2对急性脑梗死静脉溶栓患者预后不良的预测价值
18
作者 王刚 张博 +2 位作者 吕凤华 曲立新 魏伟 《检验医学与临床》 CAS 2024年第18期2642-2646,共5页
目的分析弥散加权成像-阿尔伯塔卒中项目早期计算机断层扫描(DWI-ASPECTS)评分联合血清同型半胱氨酸(Hcy)、低密度脂蛋白胆固醇(LDL-C)、脂蛋白磷脂酶A2(Lp-PLA2)对急性脑梗死(ACI)静脉溶栓患者预后不良的预测价值。方法回顾性分析2021... 目的分析弥散加权成像-阿尔伯塔卒中项目早期计算机断层扫描(DWI-ASPECTS)评分联合血清同型半胱氨酸(Hcy)、低密度脂蛋白胆固醇(LDL-C)、脂蛋白磷脂酶A2(Lp-PLA2)对急性脑梗死(ACI)静脉溶栓患者预后不良的预测价值。方法回顾性分析2021年3月至2023年9月山东大学齐鲁医院德州医院收治的102例ACI患者的临床资料,静脉溶栓3个月后以改良Rankin量表(mRS)评估患者预后,根据mRS评分将患者分为预后良好组(mRS评分≤2分)与预后不良组(mRS评分>2分)。比较两组基线资料及血清Hcy、LDL-C、Lp-PLA2水平及DWI-ASPECTS评分。绘制受试者工作特征(ROC)曲线分析DWI-ASPECTS评分联合血清Hcy、LDL-C、Lp-PLA2对ACI静脉溶栓患者预后不良的预测价值。结果预后不良组有35例患者,预后良好组有67例患者。预后不良组美国国立卫生研究院卒中量表(NIHSS)评分及Hcy、LDL-C、Lp-PLA2水平高于预后良好组,DWI-ASPECTS评分低于预后良好组,差异均有统计学意义(P<0.05)。ROC曲线分析结果显示,DWI-ASPECTS评分联合Hcy、LDL-C、Lp-PLA2评估ACI静脉溶栓患者预后不良的曲线下面积(AUC)大于DWI-ASPECTS评分、Hcy、LDL-C、Lp-PLA2单独预测的AUC(Z=3.548、3.316、3.996、4.009,P<0.05)。结论DWI-ASPECTS评分及血清Hcy、LDL-C、Lp-PLA2均对ACI静脉溶栓患者预后不良具有一定的预测价值,且其联合检测可提高预测价值。 展开更多
关键词 同型半胱氨酸 急性脑梗死 静脉溶栓 预后评估 低密度脂蛋白胆固醇 基于弥散加权成像-阿尔伯塔卒中项目早期计算机断层扫描评分
下载PDF
中性粒细胞绝对值、尿肾损伤分子1与经皮冠状动脉介入治疗后缺血再灌注急性肾损伤的相关性
19
作者 张小薇 李洋 黄杰 《全科医学临床与教育》 2024年第4期302-306,共5页
目的探讨中性粒细胞绝对值(ANC)、尿肾损伤分子1(KMI-1)与急性心肌梗死(AMI)患者经皮冠状动脉介入治疗(PCI)后缺血再灌注急性肾损伤(AKI)的相关性。方法纳入行PCI的114例AMI患者为研究对象,根据患者PCI术后72 h内是否发生AKI分为AKI组和... 目的探讨中性粒细胞绝对值(ANC)、尿肾损伤分子1(KMI-1)与急性心肌梗死(AMI)患者经皮冠状动脉介入治疗(PCI)后缺血再灌注急性肾损伤(AKI)的相关性。方法纳入行PCI的114例AMI患者为研究对象,根据患者PCI术后72 h内是否发生AKI分为AKI组和非AKI组。比较两组一般资料、PCI后2 h的ANC、尿KMI-1与其他实验室指标,分析ANC、尿KMI-1与AMI患者PCI后缺血再灌注AKI的关系。记录患者术后3个月心血管不良事件,分析ANC、尿KMI-1水平与心血管不良事件发生的关系。结果AKI组病变冠状动脉支数≥3支占比、ANC、C反应蛋白(CRP)、肌酐(Cr)、尿KMI-1水平均高于非AKI组,淋巴细胞绝对值(ALC)低于非AKI组,差异有统计学意义(Z=3.50,t分别=3.67、2.12、6.24、8.36、2.96,P均<0.05)。经logistic回归分析结果显示,ANC、Cr、尿KMI-1与AMI患者PCI后缺血再灌注AKI有关(OR分别=5.04、1.32、1.36,P均<0.05);ANC、尿KMI-1单独及联合模型预测的曲线下面积(AUC)为0.74、0.91、0.93。随访3个月发现,随着ANC、尿KMI-1升高,PCI后短期MACE发生率也随着升高(χ^(2)分别=13.77、9.36,P均<0.05)。结论ANC、尿KMI-1与AMI患者行PCI后缺血再灌注AKI有关,同时可提示AMI患者行PCI后短期预后情况,其机制与炎症反应有关。 展开更多
关键词 急性心肌梗死 经皮冠状动脉介入治疗 急性肾损伤 中性粒细胞绝对值
下载PDF
强化降脂对急性ST段抬高型心肌梗死介入治疗的影响
20
作者 赵帅 《临床合理用药杂志》 2024年第4期8-10,21,共4页
目的 观察强化降脂对急性ST段抬高型心肌梗死介入治疗的影响。方法 选取2021年1月—2022年5月白银市第一人民医院收治的急性ST段抬高型心肌梗死介入治疗患者71例,采用随机数字表法分为试验组36例和对照组35例。对照组给予注射用阿替普... 目的 观察强化降脂对急性ST段抬高型心肌梗死介入治疗的影响。方法 选取2021年1月—2022年5月白银市第一人民医院收治的急性ST段抬高型心肌梗死介入治疗患者71例,采用随机数字表法分为试验组36例和对照组35例。对照组给予注射用阿替普酶治疗,试验组在对照组治疗基础上给予阿托伐他汀钙片治疗,2组均连续治疗21 d。比较2组临床疗效,治疗前后心功能指标[左室射血分数(LVEF)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)]、血脂指标[低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)及三酰甘油(TG)]、血液生化指标[超氧化物歧化酶(SOD)、肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白T(cTnT)]。结果 试验组治疗总有效率为97.22%,高于对照组的77.14%(χ^(2)=4.777,P=0.029)。治疗21 d后,2组LVEF高于治疗前,LVESD、LVEDD小于治疗前,且试验组升高/减小幅度大于对照组(P<0.01);2组LDL-C、TC、TG水平与CK-MB、cTnT水平低于治疗前,HDL-C与SOD水平高于治疗前,且试验组降低/升高幅度大于对照组(P<0.05或P<0.01)。结论 强化降脂可提高急性ST段抬高型心肌梗死介入治疗的临床效果,可有效改善患者心功能,缓解心肌损伤,调节血脂。 展开更多
关键词 心肌梗死 急性ST段抬高型 强化降脂 介入治疗
下载PDF
上一页 1 2 91 下一页 到第
使用帮助 返回顶部